10-Q Filing

Xenetic Biosciences, Inc. CIK: 1534525 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0001683168-22-005567`
Period End Date	20220630
Filing Date	20220811
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	xenetic_i10q-063022_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 46 Income Statement 56 Cash Flow Statement 36 Stockholders Equity 25

Balance Sheet 46 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$18.24M	USD	Point-in-time
Cash	`Cash`	$14.93M	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$479.40K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$448.73K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$18.72M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.38M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.09M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.09M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	14.34M	shares	Point-in-time
Total assets	`Assets`	$19.82M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.47M	shares	Point-in-time
Total assets	`Assets`	$16.47M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	14.32M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.44M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$362.47K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$472.70K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$1.06M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$806.48K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.28M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.42M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.28M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.42M	USD	Point-in-time
Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 14,343,587 and 13,466,603 shares issued as of June 30, 2022 and December 31, 2021, respectively; 14,316,596 and 13,439,612 shares outstanding as of June 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$13.46K	USD	Point-in-time
Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 14,343,587 and 13,466,603 shares issued as of June 30, 2022 and December 31, 2021, respectively; 14,316,596 and 13,439,612 shares outstanding as of June 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$14.34K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$205.95M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$207.01M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-182.55M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-186.81M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.95M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$16.92M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$12.22M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$18.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$15.19M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$10.95M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$16.47M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$19.82M	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
Earnings Per Share, Basic	`EarningsPerShareBasic`	$-0.31	USD	2 Qtrs
Earnings Per Share, Basic	`EarningsPerShareBasic`	$-0.13	USD	1 Quarter
Earnings Per Share, Basic	`EarningsPerShareBasic`	$-0.28	USD	2 Qtrs
Earnings Per Share, Basic	`EarningsPerShareBasic`	$-0.19	USD	1 Quarter
Royalty revenue	`RoyaltyIncomeNonoperating`	$478.82K	USD	2 Qtrs
Royalty revenue	`RoyaltyIncomeNonoperating`	$287.60K	USD	1 Quarter
Earnings Per Share, Diluted	`EarningsPerShareDiluted`	$-0.28	USD	2 Qtrs
Royalty revenue	`RoyaltyIncomeNonoperating`	$416.71K	USD	1 Quarter
Earnings Per Share, Diluted	`EarningsPerShareDiluted`	$-0.31	USD	2 Qtrs
Earnings Per Share, Diluted	`EarningsPerShareDiluted`	$-0.13	USD	1 Quarter
Earnings Per Share, Diluted	`EarningsPerShareDiluted`	$-0.19	USD	1 Quarter
Royalty revenue	`RoyaltyIncomeNonoperating`	$805.70K	USD	2 Qtrs
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	8.75M	shares	2 Qtrs
Total revenue	`Revenues`	$805.70K	USD	2 Qtrs
Total revenue	`Revenues`	$287.60K	USD	1 Quarter
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	8.75M	shares	1 Quarter
Total revenue	`Revenues`	$416.71K	USD	1 Quarter
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	13.76M	shares	2 Qtrs
Total revenue	`Revenues`	$478.82K	USD	2 Qtrs
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	14.07M	shares	1 Quarter
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	8.75M	shares	2 Qtrs
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	8.75M	shares	1 Quarter
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	13.76M	shares	2 Qtrs
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	14.07M	shares	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$524.55K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.18M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.08M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.15M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$1.93M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$1.82M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$890.70K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.03M	USD	1 Quarter
Total operating costs and expenses	`OperatingExpenses`	$2.98M	USD	2 Qtrs
Total operating costs and expenses	`OperatingExpenses`	$1.42M	USD	1 Quarter
Total operating costs and expenses	`OperatingExpenses`	$3.10M	USD	1 Quarter
Total operating costs and expenses	`OperatingExpenses`	$5.11M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-2.50M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-4.31M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-2.69M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-1.13M	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$-877.00	USD	2 Qtrs
Other income (expense)	`OtherNonoperatingIncomeExpense`	$-1.08K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$238.00	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$1.12K	USD	2 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$41.87K	USD	2 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$15.96K	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$43.00K	USD	2 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$20.73K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$44.12K	USD	2 Qtrs
Total other income	`NonoperatingIncomeExpense`	$14.89K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$20.97K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$40.99K	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-1.11M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.45M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-2.67M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.27M	USD	2 Qtrs

Cash Flow Statement 36 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.11M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.45M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-2.67M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.27M	USD	2 Qtrs
Acquired in-process research and development	`ResearchAndDevelopmentInProcess`	$1.30M	USD	2 Qtrs
Acquired in-process research and development	`ResearchAndDevelopmentInProcess`	-	USD	2 Qtrs
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$17.16K	USD	2 Qtrs
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$19.09K	USD	2 Qtrs
Share-based expense	`EmployeeBenefitsAndShareBasedCompensation`	$186.21K	USD	2 Qtrs
Share-based expense	`EmployeeBenefitsAndShareBasedCompensation`	$255.47K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-1.06K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-11.58K	USD	2 Qtrs
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-141.92K	USD	2 Qtrs
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$2.20K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.82M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.25M	USD	2 Qtrs
Net cash paid to acquire in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$500.00K	USD	2 Qtrs
Net cash paid to acquire in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	-	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-500.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	2 Qtrs
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-2.25M	USD	2 Qtrs
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-3.32M	USD	2 Qtrs
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.93M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.28M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.93M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.28M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	-	USD	2 Qtrs
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	-	USD	2 Qtrs
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	$805.00K	USD	2 Qtrs
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$2.00	USD	2 Qtrs
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$1.00	USD	2 Qtrs

Stockholders Equity 25 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$9.95M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$16.92M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$15.19M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$10.95M	USD	Point-in-time
Issuance of common stock in connection with purchase of in-process research and development	`IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment`	$805.00K	USD	2 Qtrs
Issuance of common stock in connection with purchase of in-process research and development	`IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment`	$805.00K	USD	1 Quarter
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$186.21K	USD	2 Qtrs
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$109.92K	USD	1 Quarter
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$135.87K	USD	1 Quarter
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$255.47K	USD	2 Qtrs
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	1 Quarter
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	2 Qtrs
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-1.11M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-2.45M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-2.67M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.27M	USD	2 Qtrs
Ending balance, value	`StockholdersEquity`	$9.95M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$16.92M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$15.19M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$10.95M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.